Applications of Cytosorb in clinical practice

Paweł Kutnik¹, Michał Borys²

¹ Student’s Scientific Association, II Department of Anaesthesiology and Intensive Care, Medical University, Lublin, Poland
² II Department of Anaesthesiology and Intensive Care, Medical University, Lublin, Poland

Introduction and objective. Cytosorb is a haemadsorption device approved in the European Union in 2011 for cytokine adsorption. Recently, in 2018, new indications for the device use have been added, including bilirubin and myoglobin removal. This study aimed to present the results of studies pertaining to Cytosorb use in clinical practice. In subsequent sections of this review, indications for Cytosorb therapy and clinical relevance of presented evidence are listed.

State of knowledge. In clinical practice, Cytosorb has been reported as one of potential supportive therapies in patients with septic shock. There is evidence of significant reduction of interleukin 6 and vasopressors when Cytosorb is implemented. However, the decreased mortality after Cytosorb has yet to be reported. Besides cytokine adsorption, Cytosorb also collects drugs, a property that can have a beneficial effect on acute drug poisoning (anticoagulants). However, Cytosorb lowers the plasma concentration of some antibiotics which might affect the outcome of patients in septic shock. The haemadsorption device has also been researched in cardiac patients, and some reports suggest a reduced need for vasopressors and blood transfusions when therapy is installed during surgery. Other indications for Cytosorb are also reported, especially the effectiveness in decreasing bilirubin serum concentrations as treatment or bridge therapy, without affecting the albumins. Cytosorb might also be the last resort treatment in acquired haemophagocytic lymphohistiocytosis.

Conclusions. The evidence supporting the use of CytoSorb remains elusive. There is lack of large prospective studies which could provide definitive answers about the place of Cytosorb in clinical practice. There are no reports of safety and feasibility issues in all presented studies.

Key words
Critical care, ICU, haemadsorption, blood purification, Cytosorb

INTRODUCTION AND OBJECTIVE

Haemadsorption is a process in which an artificial device is placed in an extracorporeal circuit and used to bind different types of solutes from the blood. The haemadsorption devices can be connected to renal replacement therapy machines, extracorporeal membrane oxygenator, or cardiopulmonary bypass equipment. There are different haemadsorption devices on the market, including Cytosorb, oXiris or Toramycin. The first results of in vitro studies comparing these devices suggest there might be different applications for each of the adsorbents [1]. This review evaluates the reports and studies about Cytosorb.

Cytosorb is a haemadsorption device used as one of the extracorporeal blood purification techniques. The device was approved for the management of inflammatory conditions in 2011 and the registry was extended in 2018 to the treatment of high bilirubin or myoglobin concentrations. Cytosorb consists of adsorption columns made from biocompatible, highly porous polymer, with an estimated surface area over 40,000 square meters. The device targets the molecules with a wide range of size up to 60 kDa. One cycle of therapy usually takes 24 hours with blood flow set between 100–700 mL/min, and is reported as being performed daily for up to 7 consecutive days [2].

Due to Cytosorb being a relatively novel device, it is constantly researched and new applications being discovered. With 73 articles in the PubMed database and over 450 research and report documents in the Cytosorb literature database, a summary of these publications is required [3]. The aim of this article was to present and recap some of the reports about the use of CytoSorb in various clinical scenarios.

STATE OF KNOWLEDGE

Cytosorb as cytokine remover. Cytosorb was primarily presented as the cytokine remover, mainly designed for patients with severe septic shock or systemic inflammatory response syndrome. The reasoning behind using a haemadsorption device in the inflammatory process is to remove the pro-inflammatory cytokines to prevent further damage and regain the patient’s haemodynamic stability [4]. Additionally, the use of a haemadsorption device could have a beneficial impact by promoting the protection of the vascular barrier [5]. In in vitro studies, Cytosorb was proved to reduce the concentrations not only of cytokines, but also pathogen-associated molecular pattern molecules, including bacterial exotoxins which are considered triggers of an immune response[6]. Early reports on using Cytosorb showed promising results, including reduction of vasopressors with haemodynamic stabilization and reduction of capillary leakage[7]. The majority of the more prominent studies in septic shock patients present similar results confirming the reduction of vasopressor dose, with the regaining of...
**Table 1. Cytosorb in septic shock studies**

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>No. of patients</th>
<th>Reason for HA</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frieseceke et al., 2017a [9]</td>
<td>Prospective, interventional, single-centre investigation</td>
<td>20</td>
<td>Septic shock</td>
<td>Significant reduction of noradrenaline after HA introduction, improved lactate clearance, septic shock reversal in 65% of patients.</td>
</tr>
<tr>
<td>Kogelmann et al., 2017 [12]</td>
<td>Case series</td>
<td>26</td>
<td>Septic shock</td>
<td>Haemodynamic stabilization and reduction in blood lactate levels. Actual mortality lower than mortality predicted, based on APACHE II score.</td>
</tr>
<tr>
<td>Frieseceke et al., 2017b [11]</td>
<td>International registry preliminary results</td>
<td>198</td>
<td>Sepsis (135 patients). Intra- and post-operative cardiac surgery (25 patients). Other indication (38 patients)</td>
<td>Reduced interleukin-6 levels after treatment, compared to pre-treatment levels. Lower observed mortality 65% vs. predicted mortality, based on APACHE II score of 78%.</td>
</tr>
<tr>
<td>Shadler et al., 2017 [13]</td>
<td>Prospective, randomized, controlled pilot study</td>
<td>97 (47 vs. 50 control)</td>
<td>Septic shock</td>
<td>Significant interleukin-6 elimination. After adjustment for patient morbidity and baseline imbalances, no difference in mortality found between groups.</td>
</tr>
<tr>
<td>Tomescu et al., 2019 [10]</td>
<td>Case series</td>
<td>12</td>
<td>Severe acute pancreatitis</td>
<td>Use of HA was associated with improved hemodynamics and decreased inflammatory markers.</td>
</tr>
<tr>
<td>Hawchar et al., 2019 [8]</td>
<td>Prospective, randomized, controlled pilot study</td>
<td>20 (10 vs. 10 control)</td>
<td>Septic shock</td>
<td>Significantly decreased norepinephrine requirements, procalcitonin, and Big-endothelin-1 concentrations.</td>
</tr>
</tbody>
</table>

HA – haemadsorption; APACHE II – Acute Physiology, Age, Chronic Health Evaluation II

Haemodynamic stability after implementation of the haemadsorption device [Tab. 1] [8]. Interleukin-6 and lactates are cleared significantly during the treatment [9]. A study in a population with septic shock due to severe acute pancreatitis showed similar results [10]. A retrospective study of patients in the International Registry showed a reduction in observed mortality compared to the predicted mortality from 78% to 65% [11]. A similar observation was presented in a case series study performed by Kogelmann [12]. Although significant interleukin-6 reduction was observed, the only randomized prospective trial showed no significantly reduced mortality in patients supported with Cytosorb [13].

**Cytosorb in drug removal.** Although Cytosorb was designed primarily to remove inflammatory cytokines, it is not a selective adsorber. In 2002, an in vitro study of a similar device, BetaSorb, showed significant clearance of some drugs [Tab. 2] [14]. Although Cytosorb is a different device, this study is used by the manufacturer as a reference for antibiotic guidance for Cytosorb. The in vitro pharmacokinetic study performed by König et al. in 2019 estimated that one Cytosorb device absorbs approximately 400 mg of meropenem and 300 mg of ciprofloxacin [15]. Considering haemadsorption is used during septic shock, where antibiotics play a major role in treatment, the impact of removal of some antibiotics should be carefully evaluated. An inadequate, too low dose of antibiotics is associated with treatment failure [16] and the development of drug resistance in bacteria [17]. If possible, monitoring of the antibiotics serum concentration should be routinely performed when using Cytosorb. Due to the lack of in vivo pharmacokinetic model studies, a guideline for routine increase of the antibiotics remains elusive. The two case reports in vivo pharmacokinetic studies showed a significant removal of linezolid, potential significant removal of meropenem, and no impact on clindamycin clearance [18, 19].

The non-selectivity of Cytosorb can be used as an advantage, as presented in a case from 2019, when haemadsorption with continuous renal replacement therapy was successfully used in the treatment of quetiapine overdose [20]. Cytosorb was also reported to significantly remove the ticagrelor and rivaroxaban, which can potentially lead to thrombotic complications, such as acute myocardial infarction or stroke. However, in the case of severe bleeding due to those drugs, it could be used as a treatment option. In a study by Hassan et al., the use of Cytosorb during emergency cardiac surgeries was presented as likely to be beneficial in patients treated with ticagrelor or rivaroxaban [21]. In a retrospective study, Cytosorb significantly reduced the number of transfusions of red blood cell units and platelets concentrate units, shortened the ICU stay and lowered the frequency of re-thoracotomy. If confirmed in prospective studies, this approach could become routine in emergency cardiac operations. There is a need for further studies on drugs affected by the haemadsorption device, and the clinical significance of drugs removal.

**Cytosorb in cardiac surgery.** Cardiac surgery procedures are often associated with a huge release of cytokines and the development of systemic inflammatory response [22]. The reasoning behind the use of Cytosorb is to adsorb those cytokines before the systemic response sets in. Case series and retrospective studies have shown promising results [Tab. 3]. Less vasopressor was needed during the operation, and fewer renal replacement therapy implemented after the surgery in patients who used Cytosorb connected to the cardiopulmonary by-pass [23, 24]. In a study performed by Gleason et al., patients with haemadsorption had a significantly lower free haemoglobin and activated complement serum concentrations [25].

A study published in 2019 by Saller et al. on 336 patients with 168 undergoing haemadsorption in aortic surgeries, showed not only a significantly reduced need for vasopressors, but also the amount of perioperative transfusion, and positive impact on acid-base balance [26]. The case series comparing intraoperative vs. intraoperative and post-operative use of Cytosorb showed that more intense therapy (intra-operative and post-operative) might be associated with patient improvement [27]. However, two prospective, randomized, blind and controlled trials did not confirm the previous results [28, 29]. There was no significant difference in inflammatory markers, blood substitution, vasopressor need or mortality. Without large, multicentred prospective trials, the impact of haemadsorption in cardiac surgery remains elusive.
Table 2. Cytosorb in drug studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>Additional Information</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reiter et al., 2002 [14]</td>
<td>in vitro</td>
<td>Tested on BetaSorb, study provided as information on official CytoSorb website.</td>
<td>HA was associated with significant removal of antibiotics (Vancomycin, Teicoplanin), Valproic acid, Phenoibarbital, Carbamazepine, Phenytoin, Digoxin and Cyclosporine. HA did not affect aminoglycosides clearance.</td>
</tr>
<tr>
<td>Zoller et al., 2015 [18]</td>
<td>Case report</td>
<td>Patient with septic shock, Cytosorb</td>
<td>Cytosorb was associated with significant removal of linezolid. Effects of Cytosorb on meropenem remained elusive as blood samples were not collected at optimal time points.</td>
</tr>
<tr>
<td>König et al., 2019 [15]</td>
<td>in vitro</td>
<td>Tested on CytoSorb, clearance was established in normal saline, human albumin and reconstituted blood solutions</td>
<td>Cytosorb had significant clearance for meropenem and ciprofloxacin during early course of adsorption. Approximately 400 mg of meropenem and 300 mg of ciprofloxacin absorbed by Cytosorb.</td>
</tr>
<tr>
<td>Poli et al., 2019a [19]</td>
<td>Case report</td>
<td>Patient with Panton-Valentine leucocidin MRSA</td>
<td>Cytosorb did not have significant impact on clindamycin removal.</td>
</tr>
<tr>
<td>Giuntoli et al., 2019 [20]</td>
<td>Case report</td>
<td>Symptomatic voluntary overdose treated with CRRT and CytoSorb</td>
<td>HA with CRRT was safe and successful approach in treatment of severe quetiapine overdose.</td>
</tr>
</tbody>
</table>


Table 3. Cytosorb in cardiac surgeries

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>Population</th>
<th>Procedure</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bernardi et al., 2016 [28]</td>
<td>Prospective, blind, randomized</td>
<td>37 (19 HA vs. 18 control)</td>
<td>Different cardiothoracic surgeries</td>
<td>No difference between intervention and control group in inflammatory markers, blood substitution, vasopressor use or mortality.</td>
</tr>
<tr>
<td>Träger et al., 2017 [23]</td>
<td>Case series</td>
<td>57 (39 HA vs. 28 control)</td>
<td>Valve replacement due to acute endocarditis</td>
<td>Patient with HA had less pronounced need for vasopressors.</td>
</tr>
<tr>
<td>Nemeth et al., 2018 [24]</td>
<td>Observational study</td>
<td>84 (24 HA vs. 60 control)</td>
<td>Orthotopic heart transplantation</td>
<td>Patient with HA had reduced vasopressor demand and less frequent renal replacement therapy.</td>
</tr>
<tr>
<td>Kuhne et al., 2019 [27]</td>
<td>Case series</td>
<td>20 HA</td>
<td>Intraoperative (10) vs. intra-plus postoperative haemadsorption (10)</td>
<td>Similar intensive care unit and 90-day survival despite patient with intra-plus postoperative HA had longer ICU stay and higher rate of postoperative complications</td>
</tr>
<tr>
<td>Poli et al., 2019b [29]</td>
<td>Prospective, randomized, controlled trial</td>
<td>30 (15 HA vs. 15 control)</td>
<td>Different cardiothoracic surgeries</td>
<td>No difference in decrease of pro- or anti-inflammatory cytokines and lack of improvement in relevant clinical outcomes.</td>
</tr>
<tr>
<td>Saller et al., 2019 [26]</td>
<td>Retrospective, single-centre experience</td>
<td>336 (168 HA vs. 168 control)</td>
<td>Aortic surgeries</td>
<td>Patient with HA had significantly reduced need for vasopressors, amount of transfusions and improved acid-base balance.</td>
</tr>
<tr>
<td>Gleason et al., 2019 [25]</td>
<td>Prospective, randomized, controlled trial</td>
<td>38 (18 HA vs. 20 control)</td>
<td>Cardiopulmonary bypass, elective, non-emergent, complex cardiac surgeries</td>
<td>Significant reduction in free haemoglobin and activated complement in HA group.</td>
</tr>
</tbody>
</table>

HA – haemadsorption; ICU – intensive care unit

Cytosorb in other applications. As mentioned above, Cytosorb is not a selective adsorber, therefore, other molecules can be eliminated by the device. The most-reported uses are associated with bilirubin and bile acids removal. Cytosorb is a whole blood adsorbent without the need for prior plasma separation, which can be useful in albumin-bound molecules such as bilirubin and bile acids [30]. The conjugated bilirubin is a relatively small, water-soluble molecule, therefore it is easily absorbed by the device. On the other hand, unconjugated bilirubin, despite also being a relatively small molecule, is not water-soluble and is bounded to albumin particles, which are bigger than the maximum range of Cytosorb. The device breaks the binding between unconjugated bilirubin and albumin, allowing the device to absorb the bilirubin molecule without affecting patients’ albumin serum concentrations. The in vitro study from 2018 confirmed bilirubin removal by Cytosorb without affecting the albumin serum concentration during the process, which was a therapeutic issue with some other methods [31]. The case of cardiac surgery patient showed a bilirubin drop from 24.5 mg/dL to 10.8 mg/dL after three days of Cytosorb therapy[32]. The Cytosorb was reported to be useful in patient with hyperbilirubinemia due to hepatic failure [33], in drug-induced cholestasis, alcoholic hepatitis [34], and cholestasis in sepsis [35]. It was used successfully in a liver cirrhosis patient with a pre-existing hepatitis C infection [36]. Additionally, in that paper, the authors reported a significant reduction in ammonia levels, which might be used in the treatment of severe hyperammonaemia in liver failure patients. However, this requires further investigation.
and caution, as the Cytosorb device is not registered for reducing ammonia levels. Cytosorb was reported to be successful in a 9 kg paediatric patient, with a decrease in total bilirubin concentration from 54 mg/dL to 17 g/dL after a 24-hour cycle with blood flow set at 40 mL/h [37]. The largest case series study published in 2019, included 40 patients with different primary diseases, mainly cardiac. The study showed a significant reduction in bilirubin, lactates, creatine phosphokinase and lactate dehydrogenase serum concentrations [38]. To our knowledge, there are no results of studies comparing the effectiveness of Cytosorb with other methods used to lower bilirubin serum concentration.

Cytosorb was also reported as an additional support in three patients with acquired haemophagocytic lymphohistiocytosis [39, 40], a disease caused by the production of too many immune cells activated by a ‘cytokine storm’. The disease has a more than 50% mortality rate [41]. The reasoning behind using haemadsorption is to remove the cytokine that activates the immune cells, and potentially stop the disease. Cytosorb could be considered as last resort treatment option in patients with acquired haemophagocytic lymphohistiocytosis refractory to other treatments.

CONCLUSIONS

Cytosorb could become a useful tool in clinical practice, but the evidence supporting that theory remains elusive due to the lack of large prospective trials. The enrollment in such trials is challenging due to the extreme heterogeneity of the patient population, especially those in septic shock. The impact of haemoadsorption on drugs clearance should be further evaluated to ensure the optimal dosing of drugs during the therapy. Cytosorb might be a useful device in patients with liver impairment, helping to regain liver function or serve as a bridge therapy to the liver transplant. There is no strong evidence from prospective trials reporting the benefits of Cytosorb use in cardiothoracic surgeries. However, there is no report on the safety and feasibility issues in all presented studies; therefore, applications of the device should be further researched to produce definitive results.

The authors declare no conflict of interest. The study had no external funding.

REFERENCES


